Acute Amebiasis (ICD-11: 1A36.00) - Complete Coding and Diagnostic Guide

1. Introduction

Acute amebiasis represents the initial symptomatic manifestation of infection by Entamoeba histolytica, a parasitic protozoan that affects the human gastrointestinal tract. This clinical condition is characterized by an intestinal inflammatory picture that can range from mild symptoms to severe manifestations potentially fatal if not treated appropriately.

The clinical importance of acute amebiasis transcends its individual presentation, representing a significant public health problem in regions with precarious sanitary conditions and limited access to treated drinking water. The fecal-oral transmission of this parasite makes vulnerable populations particularly susceptible, including children, elderly individuals, and immunocompromised individuals.

From an epidemiological perspective, amebiasis remains endemic in various tropical and subtropical areas, although cases can occur in any geographic region due to increased global population mobility. E. histolytica differs from other non-pathogenic amoebas such as E. dispar, making precise differential diagnosis essential to guide appropriate treatment.

Correct coding of acute amebiasis using the ICD-11 system is critical for multiple reasons: it enables appropriate epidemiological tracking, facilitates allocation of public health resources, guides specific treatment protocols, and ensures appropriate reimbursement in health systems. Furthermore, accurate documentation contributes to epidemiological research that informs prevention and control policies for this intestinal parasitosis.

The transition from ICD-10 to ICD-11 brought greater specificity in the classification of Entamoeba infections, allowing clearer distinction between different clinical presentations and facilitating communication among health professionals on a global scale.

2. Correct ICD-11 Code

Code: 1A36.00

Description: Acute amebiasis

Parent category: 1A36.0 - Intestinal infection by Entamoeba

Official definition: Acute amebiasis is the symptomatic form of amebiasis resulting from infection by Entamoeba histolytica, characterized by clinical manifestations that include abdominal cramps, diarrhea of variable intensity, progressive fatigue, excessive flatulence, tenesmus (painful sensation of incomplete evacuation), and involuntary weight loss. In more severe forms of acute presentation, the patient may develop stools with visible blood (amebic dysentery), abdominal tenderness on palpation, fever, and vomiting.

This specific code should be used when the clinical presentation corresponds to the acute phase of infection, distinguishing itself from chronic complications such as intestinal ameboma or extra-intestinal manifestations of amebiasis. Appropriate coding requires diagnostic confirmation through laboratory methods that identify the presence of E. histolytica or strongly suggestive clinical evidence in appropriate epidemiological context.

The hierarchical structure of ICD-11 positions this code within the chapter of infectious or parasitic diseases, specifically in the section of intestinal infections by protozoa, reflecting the parasitic nature and primary location of the disease.

3. When to Use This Code

The code 1A36.00 should be applied in specific clinical scenarios where acute amebiasis presentation is clearly identified:

Scenario 1: Acute diarrhea with parasitological confirmation Patient presents with diarrhea lasting less than four weeks, accompanied by abdominal cramping and flatulence. Parasitological stool examination identifies trophozoites or cysts of E. histolytica, or molecular testing (PCR) confirms the presence of the parasite. The patient reports sudden onset of symptoms following possible exposure to contaminated water or food.

Scenario 2: Classic amebic dysentery Individual develops acute bloody diarrhea with mucus (appearance of "raspberry jam"), accompanied by intense tenesmus, moderate fever, and tenderness in the right lower quadrant of the abdomen. Colonoscopy reveals characteristic ulcers in "shirt button" format and biopsy or direct examination identifies trophozoites of E. histolytica with phagocytosed red blood cells.

Scenario 3: Documented epidemiological outbreak During investigation of a diarrhea outbreak in a community with inadequate sanitary conditions, multiple patients present with symptoms compatible with acute amebiasis. Even with parasitological confirmation in only some index cases, other patients with identical clinical presentation and common exposure may be coded as 1A36.00, especially when there is therapeutic response to specific amebicides.

Scenario 4: Traveler returning from endemic area Patient who recently returned from a region with high prevalence of amebiasis develops progressive watery diarrhea, intense fatigue, weight loss of 3-5 kg in two weeks, and persistent flatulence. Serological testing for anti-E. histolytica antibodies is positive and fecal antigen examination confirms active infection.

Scenario 5: Acute manifestation in immunocompromised patient Individual with immunosuppression (transplant recipient, undergoing chemotherapy, or with HIV) develops acute severe bloody diarrhea, vomiting, high fever, and significant dehydration. Rapid investigation identifies E. histolytica and the patient requires hospitalization for intensive treatment of severe acute amebiasis.

Scenario 6: Asymptomatic carrier who develops acute symptoms Patient with previous diagnosis of asymptomatic colonization by E. histolytica (not previously treated) suddenly develops symptoms of acute colitis with diarrhea, cramping, and blood in stool, characterizing the transition to symptomatic acute amebiasis that requires specific coding and immediate treatment.

4. When NOT to Use This Code

It is essential to recognize situations where code 1A36.00 is not appropriate, avoiding coding errors:

Chronic amebiasis or late complications: When the patient presents with intestinal ameboma (chronic inflammatory tumor-like mass), the correct code is 1A36.01, not 1A36.00. The ameboma represents a chronic localized complication, usually in the cecum or ascending colon, with clinical and radiological characteristics distinct from the acute phase.

Amebic liver abscess: Extra-intestinal manifestations of amebiasis, particularly liver abscess, require specific codes different from 1A36.00. Even though the abscess represents a complication of the initial infection, the coding should reflect the location and nature of the complication.

Infection by non-pathogenic amoebas: The identification of Entamoeba dispar, Entamoeba coli, Entamoeba hartmanni, or other commensal amoebas does not justify the use of 1A36.00. These species do not cause disease and their presence does not require specific amebicidal treatment. Laboratory differentiation is essential before coding.

Asymptomatic carriers: Individuals who present with E. histolytica cysts on routine examinations without any symptoms should not be coded as acute amebiasis. There is discussion about treatment of asymptomatic carriers, but coding should reflect the absence of active disease.

Acute diarrhea from other etiologies: Cases of gastroenteritis caused by viruses, bacteria (Salmonella, Shigella, Campylobacter), other parasites (Giardia, Cryptosporidium), or non-infectious causes (inflammatory bowel disease, irritable bowel syndrome) require specific codes. Clinical similarity does not justify incorrect coding without diagnostic confirmation.

Amebic colitis in resolution phase: Patients undergoing treatment for more than one week with significant clinical improvement and under outpatient follow-up may no longer meet criteria for "acute," especially if coding is for a reevaluation visit without active symptoms.

5. Step-by-Step Coding Process

Step 1: Assess diagnostic criteria

Proper coding of acute amebiasis begins with rigorous diagnostic confirmation. The diagnosis is based on:

Clinical criteria: Presence of diarrhea (watery or bloody), abdominal cramping, tenesmus, excessive flatulence, and in severe cases, fever and vomiting. Epidemiological history of exposure to inadequate sanitary conditions or recent travel strengthens suspicion.

Laboratory confirmation: The gold standard includes microscopic identification of E. histolytica trophozoites containing phagocytosed red blood cells in fresh stool, detection of specific antigens by ELISA, or molecular tests (PCR) that differentiate E. histolytica from E. dispar. Serial parasitological examinations (three samples) increase diagnostic sensitivity.

Complementary evaluations: Colonoscopy may reveal characteristic ulcers, and biopsies demonstrate trophozoites in the mucosa. Serology for anti-E. histolytica antibodies is useful but may remain positive for years after prior infection.

Step 2: Verify specifiers

Determine the severity and characteristics of the presentation:

Mild severity: Diarrhea without blood, tolerable symptoms, patient maintains oral hydration, without signs of systemic toxicity.

Moderate severity: More frequent diarrhea, presence of occasional blood, mild to moderate dehydration, need for intravenous rehydration.

Severe severity: Frank dysentery, high fever, severe dehydration, signs of systemic toxicity, need for hospitalization.

Duration: Confirm that symptoms are in the acute phase (generally less than four weeks), distinguishing from chronic or recurrent presentations.

Step 3: Differentiate from other codes

1A36.01 - Intestinal ameboma: This condition represents a chronic granulomatous complication that forms a palpable mass, usually in the cecum. It differs from acute amebiasis by subacute or chronic presentation, presence of mass on palpation or imaging studies, and frequently a history of prior amebiasis. Radiologically, it may simulate neoplasia. Use 1A36.01 when there is confirmation of chronic inflammatory mass, not for acute diarrhea.

Other codes for intestinal infection: Differentiate from shigellosis, salmonellosis, giardiasis, and other causes of infectious diarrhea through specific laboratory confirmation.

Step 4: Required documentation

Checklist for adequate documentation:

[ ] Date of symptom onset (characterizing acute phase)
[ ] Detailed description of symptoms (type of diarrhea, presence of blood/mucus)
[ ] Epidemiological history (travel, exposure, outbreak)
[ ] Results of parasitological examinations with method used
[ ] Results of serological or molecular tests when performed
[ ] Assessment of severity and need for hospitalization
[ ] Exclusion of differential diagnoses considered
[ ] Therapeutic plan instituted (confirms definitive diagnosis)
[ ] Response to specific treatment (when available in follow-up evaluations)

6. Complete Practical Example

Clinical Case:

A 34-year-old male patient presents to the emergency department with a complaint of diarrhea for 5 days. He reports that symptoms began with diffuse abdominal cramping and liquid bowel movements, initially without blood, occurring 6-8 times daily. Over the past two days, he noticed the presence of blood and mucus in his stool, with a reddish gelatinous appearance. He reports intense tenesmus, sensation of incomplete evacuation, and progressive fatigue. He has lost approximately 4 kg since the onset of symptoms. He denies fever initially, but over the past 24 hours has presented with an axillary temperature of 38.2°C.

Epidemiological history reveals that the patient returned two weeks ago from a work trip where he consumed untreated spring water and food under questionable hygienic conditions. He denies recent antibiotic use or other medications. He has no known comorbidities.

On physical examination: patient is dehydrated (dry mucous membranes, decreased skin turgor), abdomen slightly distended, tender to palpation in the right and left lower quadrants, no palpable masses, increased bowel sounds. Temperature: 38.0°C, HR: 96 bpm, BP: 110/70 mmHg.

Tests ordered in the emergency department: complete blood count showed mild leukocytosis (12,000/mm³) with left shift. Fresh stool parasitological examination revealed the presence of Entamoeba histolytica trophozoites with phagocytosed red blood cells. Fecal antigen test for E. histolytica positive. Stool culture negative for pathogenic bacteria.

Patient was given intravenous hydration, prescribed metronidazole followed by paromomycin for complete treatment, and counseled on hygiene measures. Outpatient reevaluation scheduled for 7 days.

Step-by-Step Coding:

Criteria analysis:

✓ Acute symptoms (5 days duration)
✓ Diarrhea with progression to dysentery
✓ Abdominal cramping and tenesmus present
✓ Weight loss and fatigue documented
✓ Fever in more advanced phase
✓ Definitive laboratory confirmation (trophozoites with phagocytosed red blood cells)
✓ Positive specific antigen test
✓ Compatible epidemiological history

Code selected: 1A36.00 - Acute amebiasis

Complete justification: The code 1A36.00 is appropriate because the patient presents all defining criteria for acute amebiasis: recent symptomatic manifestation (5 days), characteristic clinical presentation with progression from watery diarrhea to dysentery, presence of systemic symptoms (fever, fatigue, weight loss), and unequivocal parasitological confirmation through microscopic identification of pathogenic trophozoites and positive antigen test.

The presentation does not correspond to chronic complications such as ameboma (absence of palpable mass or imaging findings), nor to extra-intestinal manifestations. The duration of symptoms characterizes an acute phase, not chronic. The exclusion of other etiologies through negative stool culture and the expected response to specific amebicidal treatment confirm the diagnosis.

Applicable complementary codes:

Dehydration code if clinically significant and requiring specific intervention
Fever code if documented as a prominent manifestation
Z code (factors related to health status) for recent travel if relevant for epidemiological surveillance

7. Related Codes and Differentiation

Within the Same Category:

1A36.01 - Intestinal ameboma:

When to use 1A36.01: Use this code when the patient presents with a chronic granulomatous complication of amebiasis, characterized by a localized inflammatory mass, usually in the cecum or ascending colon. The ameboma develops weeks to months after acute infection, presenting as a palpable mass, localized abdominal pain, and partial obstructive symptoms. Imaging studies (computed tomography, colonoscopy) demonstrate a tumor-like lesion that may simulate neoplasia.

Main difference: Acute amebiasis (1A36.00) is characterized by recent diffuse symptoms (diarrhea, dysentery), while ameboma (1A36.01) represents a localized, chronic granulomatous reaction with mass formation. Temporally, ameboma is a late complication, not an acute manifestation. Clinically, ameboma may present with obstructive symptoms without significant diarrhea, contrasting with the prominent diarrheal presentation of the acute phase.

Differential Diagnoses:

Shigellosis (specific code in ICD-11): Distinguished by more abrupt onset, high fever from the beginning, profuse bloody diarrhea, and identification of Shigella in stool culture. Epidemiologically, shigellosis frequently occurs in outbreaks with rapid person-to-person transmission.

Ulcerative colitis: Chronic inflammatory bowel disease with recurrent bloody diarrhea, but without parasitic identification. History of previous episodes, endoscopic findings of continuous inflammation (not focal ulcerations), and biopsy without parasites differentiate it from amebiasis.

Acute diverticulitis: May cause abdominal pain and altered bowel habits, but typically without profuse bloody diarrhea. Imaging studies show diverticular inflammation, not diffuse ulcerations of the colonic mucosa.

8. Differences with ICD-10

Equivalent ICD-10 code: A06.0 - Acute amebic dysentery

Main changes in ICD-11:

The transition from ICD-10 to ICD-11 brought greater specificity in the classification of Entamoeba infections. In ICD-10, code A06.0 specifically encompassed "acute amebic dysentery," emphasizing presentation with blood in stool. ICD-11, with code 1A36.00, expands the concept to include the entire spectrum of acute symptomatic amebiasis, not just the dysenteric form.

The hierarchical structure improved significantly: ICD-11 clearly groups Entamoeba intestinal infections under 1A36.0, with specific subdivisions (1A36.00 for acute form, 1A36.01 for ameboma), while ICD-10 had less intuitive organization.

Terminology also evolved: ICD-11 uses "acute amebiasis" instead of "acute amebic dysentery," recognizing that not all acute cases present frank dysentery, but may have watery diarrhea without blood, especially in early phases.

Practical impact of these changes:

Healthcare professionals should recognize that code 1A36.00 captures a broader spectrum of acute presentations, not just cases with evident bleeding. This improves the sensitivity of epidemiological surveillance and allows more complete disease tracking. Health information systems needed to update conversion tables, and coder training became essential to ensure adequate transition. Greater specificity facilitates clinical research and outcomes analysis, allowing more precise studies on different presentations of amebiasis.

9. Frequently Asked Questions

1. How is definitive diagnosis of acute amebiasis made?

Definitive diagnosis requires laboratory confirmation of the presence of Entamoeba histolytica. The classic method is parasitological examination of stool, ideally in a fresh sample (less than 30 minutes after defecation) to visualize motile trophozoites. Identification of trophozoites containing phagocytosed red blood cells is highly specific for E. histolytica. Since parasitic shedding is intermittent, collection of three samples on alternate days is recommended. Fecal antigen detection tests by ELISA offer greater sensitivity and specificity, differentiating E. histolytica from non-pathogenic species. Molecular methods (PCR) are more sensitive and specific, but less available. Serology detects anti-E. histolytica antibodies, useful in cases with negative stool examinations, but does not differentiate current from previous infection. In severe or atypical cases, colonoscopy with biopsy may be necessary, revealing characteristic ulcers and allowing histological identification of parasites.

2. Is treatment available in public health systems?

Medications for treating acute amebiasis are generally available in public health systems in various countries, as they are part of essential medicine lists recommended by international health organizations. Standard treatment includes two components: a tissue amebicide (such as metronidazole or tinidazole) to eliminate invasive trophozoites, followed by a luminal amebicide (such as paromomycin or iodoquinol) to eradicate intestinal cysts. Specific availability varies according to the local health system, but most public services maintain at least metronidazole in their basic pharmacies. In endemic regions, these medications are priorities in parasite control programs. Patients should consult local health services regarding availability and access to these treatments.

3. How long does treatment for acute amebiasis last?

Complete treatment of acute amebiasis typically lasts 10 to 14 days, divided into two phases. The first phase uses tissue amebicide (metronidazole 500-750mg three times daily for 7-10 days, or tinidazole in a single daily dose for 3-5 days) to eliminate invasive trophozoites in the intestinal wall. The second phase employs luminal amebicide (paromomycin 25-35mg/kg/day divided into three doses for 7 days) to eradicate cystic forms in the intestinal lumen and prevent recurrence or transmission. Some protocols administer both phases simultaneously. Clinical improvement generally occurs within 3-5 days after starting treatment, but it is essential to complete the entire course for parasitological cure. Severe or complicated cases may require prolonged hospitalization. Follow-up examinations are recommended 2-4 weeks after treatment completion to confirm parasitic eradication.

4. Can this code be used in medical certificates and official documents?

Yes, code 1A36.00 can and should be used in medical certificates, clinical reports, health declarations, and other official documents when appropriate. ICD-11 coding is internationally recognized as the standard system for disease classification, being accepted by medical institutions, health systems, insurance companies, and government agencies. In medical certificates, one may choose to include only the code (1A36.00) or add the description "acute amebiasis" according to institutional preference or local legal requirements. Use of the code facilitates administrative processing, ensures relative confidentiality (the code is less identifiable than full description), and allows appropriate epidemiological tracking. Professionals should follow local regulations regarding medical privacy when documenting diagnoses in documents that will be shared with third parties.

5. Can acute amebiasis recur after adequate treatment?

Recurrences can occur, but are relatively uncommon after complete and adequate treatment. When they do occur, they generally result from incomplete treatment (failure to complete the luminal phase), reinfection from new exposure to cysts, or rarely, parasitic resistance. Reinfection is more likely in individuals who remain in environments with inadequate sanitary conditions or who have not adopted preventive measures. To minimize recurrences, it is essential to complete both phases of treatment (tissue and luminal), perform follow-up examinations to confirm parasitological cure, and implement rigorous preventive measures (hand hygiene, consumption of treated water, food precautions). Patients with recurrent episodes should be investigated for predisposing conditions such as immunosuppression, and evaluated for the possibility of continuous reinfection in the home or occupational environment.

6. Can children and pregnant women receive treatment for acute amebiasis?

Yes, but with special considerations. In children, acute amebiasis can be particularly severe due to increased risk of dehydration and malnutrition. Treatment is essential and medications can be used with dose adjustment based on body weight. Metronidazole is generally safe in pediatrics, and paromomycin (not systemically absorbed) is particularly suitable for children. In pregnant women, the situation requires careful risk-benefit evaluation. Metronidazole was traditionally avoided in the first trimester, but recent evidence suggests relative safety when necessary. Paromomycin is considered safer in pregnancy as it is not systemically absorbed, and is often chosen for treating pregnant women, especially in the first trimester. Severe cases may require immediate treatment regardless of trimester, as the risks of untreated disease outweigh medication risks. Decisions should be individualized with specialized medical follow-up.

7. What are the main complications of untreated acute amebiasis?

Untreated acute amebiasis can progress to serious complications. The most severe intestinal complication is fulminant colitis with intestinal perforation, causing peritonitis and sepsis, with high mortality. Toxic megacolon, although rare, can occur with massive colonic dilation. Chronically, ameboma (granulomatous mass) or intestinal stenosis may develop. The most common extra-intestinal complication is amebic liver abscess, occurring in a small percentage of cases through portal hematogenous dissemination. Abscesses may rupture into the peritoneal, pleural, or pericardial cavity. Other rare complications include cerebral, pulmonary, or cutaneous amebiasis. Severe dehydration and malnutrition are significant complications, especially in children and elderly patients. Massive intestinal bleeding, although uncommon, can occur in severe cases. Early treatment prevents virtually all these complications, emphasizing the importance of rapid diagnosis and adequate therapy.

8. How to prevent amebiasis and avoid transmission to close contacts?

Prevention of amebiasis is based on hygiene and sanitation measures. Individual measures include: rigorous hand washing with soap and water after using the bathroom and before handling food; consumption of only treated water (boiled, filtered, or chlorinated); avoiding consumption of raw vegetables not adequately sanitized in endemic areas; thoroughly cooking food; avoiding ice from unknown sources. To prevent household transmission, diagnosed patients should use an exclusive bathroom when possible, or ensure rigorous disinfection after use; not handling food for other people during symptomatic phase; washing bed linens and personal clothing separately with hot water. Community measures include adequate basic sanitation, treatment of water supply, health education about fecal-oral transmission, and identification/treatment of asymptomatic carriers in high-risk environments (food handlers, healthcare professionals). Travelers to endemic areas should receive specific preventive guidance before travel.

Conclusion:

Proper coding of acute amebiasis using ICD-11 code 1A36.00 is fundamental for appropriate clinical management, effective epidemiological surveillance, and adequate allocation of public health resources. This guide provides healthcare professionals with the necessary tools to correctly identify cases that should receive this code, differentiate them from similar conditions, and properly document the diagnosis. Clear understanding of diagnostic criteria, clinical manifestations, and distinctions from other presentations of amebiasis ensures accurate coding that benefits both individual patient care and public health initiatives on a global scale.

External References

This article was prepared based on reliable scientific sources:

References verified on 2026-02-04

Acute Amebiasis

Compartir